The company revealed its new Always Solving corporate identity following its eventual separation from Valvoline.
On Oct. 3, 2016, Ashland revealed a new corporate identity, Always Solving, furthering its competitive strategy following its eventual separation from Valvoline. In a press announcement, the company said Always Solving reflects the company’s positioning and people across diverse industries as broad as pharmaceuticals, automotive, personal care, paints, adhesives, biofunctionals, and more.
Bill Wulfsohn, Ashland CEO and chairmen, developed a competitive strategy that empowers each of Ashland’s chemical businesses to develop its own comprehensive strategic approach as to where to compete and how to win in their marketplace. Ashland will continue fostering growth through a pipeline of innovations and sales opportunities and continue capturing value delivered to customers while driving its cost competitiveness.
In a press announcement, the company reiterated its corporate focus on safe, compliant, and responsible operations and commitment to doing business with integrity and respect for all people and the world. The company has made formal commitments to improve the environmental, health, safety, and security performance for facilities, processes, and products throughout the entire operating system. Forty-six Ashland sites have received Responsible Care certification, including three facilities earlier this year.
Source: Ashland
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.